<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>TRIB2 is a potent oncogene, elevated in a subset of human <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with a mixed myeloid/lymphoid phenotype and NOTCH1 mutations </plain></SENT>
<SENT sid="1" pm="."><plain>Although rare in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, activating NOTCH1 mutations occur in 50% of <z:hpo ids='HP_0000001'>all</z:hpo> T cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>TRIB2 is a NOTCH1 target gene that functions in the degradation of key proteins and modulation of MAPK signalling pathways, implicated in haematopoietic cell survival and proliferation </plain></SENT>
<SENT sid="3" pm="."><plain>This study showed that TRIB2 expression level is highest in the lymphoid compartment of <z:mpath ids='MPATH_458'>normal</z:mpath> haematopoietic cells, specifically in T cells </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of TRIB2 expression across 16 different subtypes of human <z:mpath ids='MPATH_336'>leukaemia</z:mpath> demonstrated that TRIB2 expression was higher in ALL phenotypes versus <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0005395'>other phenotypes</z:mp> including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (CLL), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="5" pm="."><plain>A T cell profile was distinguished by high TRIB2 expression in <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant haematopoiesis </plain></SENT>
<SENT sid="6" pm="."><plain>High TRIB2 expression was seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype and correlated with NOTCH signalling pathways </plain></SENT>
<SENT sid="7" pm="."><plain>High TRIB2 expression correlated with NOTCH1/FBXW7 mutations in a paediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> cohort, strongly linking NOTCH1 activation and high TRIB2 expression in paediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The relationship between TRIB2 and T cell signalling pathways uniquely identifies <z:mpath ids='MPATH_336'>leukaemia</z:mpath> subtypes and will be useful in the advancement of our understanding of T cell and ALL biology </plain></SENT>
</text></document>